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Mutations in ABCC6 cause pseudoxanthoma elasticum (PXE), a heritable disease that affects elastic fibers. Thus 
far, more than 200 mutations have been characterized by various PCR-based techniques (primarily direct 
sequencing), identifying up to 90% of PXE causing alleles. This study wanted to assess the importance of 
deletions and insertions in the ABCC6 genomic region, which is known to have a high recombinational potential. 
To detect ABCC6 deletions/insertions, which can be missed by direct sequencing, multiplex ligation-dependent 
probe amplification (MLPA) was applied in PXE patients with an incomplete genotype. MLPA was performed 
in 35 PXE patients with at least one unidentified mutant allele after sequencing of exon/intron boundaries and 
exclusion of the recurrent exon 23-29 deletion. Six multi-exon deletions and four single-exon deletions were 
detected.  
Using MLPA in addition to sequencing, we expanded the ABCC6 mutation spectrum with 9 novel deletions and 
characterized 25% of unidentified disease alleles. Our results further illustrate the instability of the ABCC6 
genomic region and stress the importance of screening for deletions in the molecular diagnosis of PXE. 


































































Pseudoxanthoma elasticum (PXE; OMIM#264800) is an autosomal recessive disorder, affecting the skin 
(yellowish papules, increased laxity in flexural areas), the eyes (peau d’orange, angioid streaks, retinal 
hemorrhage and vision loss) and the cardiovascular system (occlusive artery disease, gastro-intestinal bleeding) 
(Hu et al. 2003; Vanakker et al. 2008). The disease results from abnormal calcification and fragmentation of 
elastic fibers in the middermis, in the Bruch’s membrane of the retina and in the elastic laminae of blood vessels 
(Neldner 1988). 
PXE is caused by mutations in ABCC6 (OMIM#603234), a gene spanning 74 kb on chromosome 16p13.1. 
ABCC6 encodes an adenosine triphosphate (ATP)-binding cassette transporter (subfamily C), previously referred 
to as multidrug resistance protein 6. This transmembrane protein is expressed mainly in liver and kidney and to a 
much lower extent in the tissues affected in PXE. The substrate(s) transported by ABCC6 is unknown and PXE 
is now considered a metabolic disease (Jiang et al. 2009; Le Saux et al. 2006). 
At present, more than 200 different ABCC6 mutations have been identified. These are primarily located at the 3’ 
end of ABCC6 between exons 24 and 30. Two of these mutations are particularly prevalent, a deletion of exon 
23-29 (del23-29) and p.R1141X (c.3421C>T) (Chassaing et al. 2005; Miksch et al. 2005; Pfendner et al. 2007). 
To date, only 16 different large ABCC6 deletions (entire exons, whole gene deletions) have been identified in 
PXE patients (Bergen et al. 2000; Chassaing et al. 2007; Katona et al. 2005;  Le Saux et al. 2001; Meloni et al. 
2001; Miksch et al. 2005; Ringpfeil et al. 2001). Nevertheless, ABCC6 is extremely prone to genomic 
rearrangements due to the high content of repetitive elements in all introns and in the genomic sequences 
surrounding the gene (Ringpfeil et al. 2001).  
We hypothesized that, due to the documented instability of the ABCC6 genomic region, the unidentified mutant 
alleles remaining after direct sequencing and screening for the recurrent exon 23-29 deletion, may consist of 
deletions and/or insertions. In this study we aimed to screen for the presence of such deletions and/or insertions 
using the multiplex ligation-dependent probe amplification (MLPA) technique. Our cohort consisted out of 35 
patients with a clear-cut diagnosis of PXE but with only one or no ABCC6 mutations identified by current PCR 
based techniques (Schouten et al. 2002). Recently, a PXE-like disease (OMIM#610842) that shares a significant 
phenotypical overlap with PXE was described. Therefore, patients whose genotypes remained incompletely 
ascertained after MLPA analysis were screened for the possible presence of mutations in GGCX 
(OMIM#137167), the gene responsible for the PXE-like syndrome (Vanakker et al. 2007). 
PATIENTS AND METHODS 
Patients and samples 
In a cohort of 331 clinical and biopsy-proven PXE patients of Belgian,-French or -Italian ancestry, an extended 
analysis of ABCC6 coding regions and exon/intron boundaries was performed by the traditional approach 
described previously (Hu et al. 2004). After this analysis, we failed to identify ABCC6 mutations in one or both 
alleles in 35 patients (9 male, 26 female). In 29 of these patients, only a single ABCC6 mutation was found while 
we could not detect any ABCC6 mutation in 6 affected subjects, representing a total of 41 unidentified alleles. 
































































The PXE diagnosis was made by experienced clinicians (ADP, OMV, LM). The clinical diagnosis was based on 
the presence of ophthalmological manifestations (including retinal peau d’orange and/or angioid streaks) and 
skin involvement (macroscopic skin lesions including yellowish papules and/or plaques in the neck and other 
flexural areas and microscopic skin lesions on full thickness skin biopsy) (Lebwohl et al. 1994). All patients had 
a positive skin biopsy with calcification and fragmentation of elastic fibers.  
This study was reviewed and approved by the Ethics Committee of the Ghent University Hospital and informed 
consent was obtained from all participating patients. 
 
MLPA analysis   
Genomic DNA was isolated from peripheral blood or fibroblasts using a Puregene kit or QIA-amp DNA 
extraction respectively.  
For MLPA analysis, the commercially available SALSA reagent set p092B kit was used (MRC-Holland, 
Amsterdam, The Netherlands, www.mrc-holland.com). This kit contained 23 probes corresponding to ABCC6 
exons 2, 4, 5, 7-15, 17, 18, 21-28 and 30 and 12 control probes for quality control. The p092B kit lacked probes 
for ABCC6 exons 1, 3, 6, 16, 19, 20, 29 and 31. Because ABCC1 is in close proximity to ABCC6 (6.5 kb 
telomeric), an ABCC1 probe was also included. The construction of the kit precludes generation of signals from 
the ABCC6 pseudogenes (Schouten et al. 2002). 
MLPA analysis was performed according to the manufacturer’s recommendations (www.mlpa.com), using 100 
ng of DNA in a 5 µl reaction. MLPA generated fragments were detected using an ABI 3730 Genetic Analyzer 
(Applied Biosystems, Foster City, California, USA, www3.appliedbiosystems.com) with ROX500 (Applied 
Biosystems, Foster City, California, USA, www3.appliedbiosystems.com) as an internal size standard. The 
genemapper software (Applied Biosystems, Foster City, California, USA, www3.appliedbiosystems.com) was 
used to calculate fragment size and concentration, whereas the quantification analysis was performed using 
Coffalyzer (MRC Holland, Amsterdam, the Netherlands, www.mrc-holland.com). All samples were tested in 
duplicate.  
 
Confirmation by probe complementarity experiments 
During an MLPA experiment, exon specific probes hybridize to the DNA sample. The presence of deletions 
and/or duplications can be detected by a decrease/increase in the annealing of probes. However, a decrease in 
probe/DNA binding can also be the result of differences in nucleotide sequence between MLPA probes and their 
target sequences due to genomic variations such as Single Nucleotide Polymorphisms (SNPs). This may give 
rise to false positive results. To ascertain the presence of SNPs, we sequenced the region covered by the probes 
using an ABI 3730 Genetic Analyzer (Applied Biosystems, Foster City, California, USA, 
www3.appliedbiosystems.com). Primers and methods were used as described in Hu et al. 2004. The nucleotide 
sequence of the probes was obtained from MRC-Holland, Amsterdam, The Netherlands. 
 
Confirmation by long-range PCR experiments 
Long-range PCR was performed using an Iproof high fidelity polymerase (Biorad, Nazareth, Belgium, 
www3.bio-rad.com). In a first step, primer sets flanking the deleted region were designed and optimized. PCR 
conditions for long-range amplification were as follows [98°C 30’’, (98°C 10’’, annealing temperature 30’’, 
































































72°C 3’)x32, 72°C 10’]. After amplification, DNA fragments were visualized on a 0.8% agarose gel. Deletion 
break points were characterized by excision of shorter DNA fragments and direct sequencing. The sequences of 
the PCR products were compared to the ABCC6 genomic reference sequence (RefSeq NM_001171.5). 
 
Confirmation by array comparative genomic hybridization (aCGH) 
To confirm whole ABCC6 gene deletions, a Whole Human Genome Oligo Microarray 4x44K (Agilent 
technologies, Santa Clara, California, USA, www.agilent.com) was used with particular focus on chromosome 
16.  For smaller multi-exon deletions, an array specific to chromosome 16 with a high probe density for the 
chr16:15687873-17130000 region was designed. Probes were selected from the high-density comparative 
genomic hybridization database (HD CGH, Agilent Technology eArray; 
https://earray.chem.agilent.com/earray/). After submitting the selected probes to the UCSC genome browser 
(http://genome.ucsc.edu/), the probe density around all ABCC6 exons was checked. The presence of the ABCC6 
pseudogenes rendered probe design more difficult for exons 1 through 9, with little or no probes being available 
in the HD CGH Database. In each hybridization experiment, patient and control DNA were labelled with CY3 
(green) and CY5 (red) respectively. 
 
GGCX sequencing 
In those patients with an incomplete genotype following MLPA (n=28), the coding sequence of GGCX (RefSeq 
NM_000821.4) was verified using primers and PCR conditions as described previously (Li et al, 2008). Patients 
harbouring homozygous or compound heterozygous mutations in specific regions of GGCX develop the PXE – 
like syndrome, which associates skin and eye features of PXE with a generalized cutis laxa and vitamin K- 
dependent clotting deficiency (Vanakker et al, 2007). The disease potential of identified variants was estimated 




To identify deletions and insertions in ABCC6 we performed MLPA in PXE patients with unidentified mutant 
alleles. Of the 41 unknown disease alleles from 35 patients, 11 alleles could be further identified by MLPA. 
These included one intragenic multi-exon deletion, four whole gene deletions and six single-exon deletions. 
(Figure 1) The multi-exon deletion in patient 3 encompassed exons 24 to 27. The four whole gene deletions in 
patients 13, 20, 26 and 34 expanded beyond ABCC6 as indicated by the 0.5 ratio for the ABCC1 control probe. 
The single-exon deletions in patients 4, 6, 7, 16, 28 and 32 involved exons 30, 14, 2, 9, 24 and 30 respectively. 
All these exons encode an intracellular domain of ABCC6, except for exon 2, which corresponds to a 
transmembrane segment as predicted by the human protein reference database. 
 
Confirmation of the intragenic multi-exon deletion and the whole gene deletions 
The multi-exon and whole gene deletions were confirmed by aCGH in all patients except patient 20 for whom no 
appropriate DNA for array analysis was available. The aCGH analysis enabled simultaneously breakpoint 
determination for patients 3, 13, 26 and 34. (Figure 2A) The minimum/maximum length of the deletions were 
































































5.5-10.5kb, 784-1642kb, 1257-1955kb and 2756-2958kb respectively. (Table I) The exact breakpoints of patient 
3 could be determined by long-range PCR and measured 8118 bp (c.3307-1006_3735+1582del). (Table II) 
 
Confirmation of the single-exon deletions 
To exclude false positive MLPA results, sequence similarities between the MLPA probes and patient’s DNA 
were compared in the case of single exon deletions. The sequences were identical for patient 4, 16 and 32, 
validating our results. (Table II) Patient 7 exhibited a homozygous nucleotide variant in the probe-binding site. 
However, we verified that this nucleotide change had no influence on probe binding efficacy with an MLPA 
experiment using a control sample containing the same variant (data not shown).  In contrast, a false positive 
MLPA result was obtained as a consequence of the presence of a known heterozygous point mutation in the 
probe annealing region in patient 6 (c.1798C>T; p.R600C). The presence of a heterozygous variant in the same 
region demonstrates that the patient is not hemizygous for this region. (Table II) 
In patient 32, an aCGH experiment could be performed, demonstrating that the deletion comprises exon 30 and 
31 and is 5-6kb in length. (Figure 2B) For the other patients no fresh DNA was available for aCGH analysis.  
To characterize the deletion in patient 28, long-range PCR was carried out to amplify across the deleted region 
and the resulting PCR product was sequenced. The deletion measured 1754 bp (c.3307-904_3506+660del). 
(Table II) Unfortunately, our various attempts to determine the breakpoints for patients 4, 7 and 16 using many 
different primer pairs were unsuccessful. 
 
Finally, we performed MLPA analysis in patients with a previously identified apparently homozygous p.R1141X 
mutation (exon 24) to verify whether the subjects were indeed homozygotes or whether this variant was paired 
with a deletion of the exon 24 region. Surprisingly, we identified deletions removing the region of exon 24 
indicating that a non-negligible proportion of patients with R1141X were in fact compound heterozygous. 
 
Overall, out of 35 patients with incomplete genotypes, MLPA analysis allowed us to obtain the complete 
genotype for 7 patients (20%) and a partial characterization for 25 affected individuals, while the disease-causing 
alleles remained undetected in only 3 subjects with biopsy-proven diagnosis.  
Subsequently, the DNA samples of the 28 patients remaining with an incomplete genotype after MLPA were 
screened for possible nucleotide changes in GGCX that could account for the missing causative alleles. Because 
no MLPA probes were available to search for GGCX deletions we used direct sequencing of exonic regions 
only. No mutation was detected, though a heterozygous variant was found in exon 10 (p.S452T) for one patient. 
This nucleotide variant was not present in 100 control samples (200 alleles) but was predicted to be benign by in 
silico analysis. 
DISCUSSION 
PXE, a heritable disorder affecting the skin, eyes and the cardiovascular system, is caused by mutations in the 
ABCC6 gene (Bergen et al. 2000; Le Saux et al. 2000; Neldner 1988; Ringpfeil et al. 2000). Of the various 
techniques applied to mutation analysis of ABCC6, the currently prevailing and most efficient technique is direct 
sequencing with a mutation detection rate of about 90%. Various deletions involving parts or the whole ABCC6 
gene have been previously reported (Bergen et al. 2000; Chassaing et al. 2007; Katona et al. 2005; Le Saux et al. 
































































2001; Meloni et al. 2001; Miksch et al. 2005; Ringpfeil et al. 2001). Small or large deletions are expected to 
make up for the bulk of the unidentified alleles because heterozygous middle-sized deletions are notoriously 
difficult to detect with traditional PCR-based assays. Furthermore, the presence of numerous repetitive elements 
makes the ABCC6 region subject to genomic rearrangements.  
 
Deletions often originate from homologous recombination between identical sequences of repeated DNA. 
Several types of repeats (long and short interspersed nuclear elements, Alu repeats,…) are abundantly present in 
the intra –and extragenic region of ABCC6 (UCSC genome browser, http://genome.ucsc.edu/) (Chassaing et al. 
2007, Symmons et al. 2008). Some of them are strongly suspected to have caused the recurring del23-29 
deletion and the unique exon 15 deletion (Le Saux et al 2001; Ringpfeil et al 2001). Similarly, such 
rearrangements may have been responsible for the existence of the two ABCC6 pseudogenes, which further 
illustrates the recombinational potential of this region of chromosome 16. Indeed, Cai et al. have shown that the 
ABCC6 pseudogenes contribute to mutations in the parent gene (Cai et al. 2001; Symmons et al. 2008). Until 
now, a total of 16 different large deletions (exons, whole gene deletions) have been described (Bergen et al. 
2000; Chassaing et al. 2007; Katona et al. 2005; Le Saux et al. 2001; Meloni et al. 2001; Miksch et al. 2005; 
Ringpfeil et al. 2001). Because of the wide variety of repeat elements in the ABCC6 region, we anticipated that 
several of the unidentified mutant alleles in our PXE cohort would consist of deletions and insertions. 
 In our patients with incomplete genotypes, we identified a deletion in approximately 25% of the uncharacterized 
alleles. Nine of the deletions were novel, hereby increasing the spectrum of known large ABCC6 deletions from 
16 to 25.   
Of the 10 patients in whom a deletion was detected, four carried a deletion removing the whole ABCC6 gene. In 
these 4 patients, the absence of ABCC1 was also observed indicating that these deletions were not restricted to a 
single gene. ABCC1 is located 6.5kb telomeric to ABCC6 and encodes a plasma membrane drug-efflux pump 
(ABCC1) closely related to ABCC6. Array CGH revealed that the whole gene deletions were of variable length 
(784-1642kb, 1257-1955kb and 2756-2958kb). Moreover, aCGH showed the absence of several other genes as 
summarized in table I, indicating that the deletions extend far beyond ABCC1-ABCC6. 
Besides expanding the ABCC6 mutation spectrum, our results have several practical implications. First, by 
increasing the mutation detection rate, familial screening and genetic counselling can be improved. Second, the 
identification of deletions is of relevance for the interpretation of direct sequencing results. Every patient 
diagnosed with a homozygous ABCC6 mutation could in fact be compound heterozygous for that particular 
mutation and a deletion of the corresponding region. In the molecular analysis of ABCC6, verification of the 
multi-exon deletion 23-29 and analysis of other recurrent mutations followed by sequencing of the whole coding 
region remain the first essential steps (Vanakker et al. 2008). If after this approach, one or more mutant alleles 
remain undetected or in the case of a homozygous mutation (and unavailable parents), MLPA can be applied to 
search for deletions or duplications. 
Because of the phenotypic overlap between PXE and the PXE-like syndrome, we analysed the GGCX gene in 
the 28 patients remaining with an incomplete genotype after MLPA but did not detect mutations nor functional 
polymorphisms in this gene.  
One may note that the MLPA kit we used in this study covered only 23 of the 31 exons of ABCC6. Nevertheless, 
the mutational screening we applied was quite effective since we identified 10 deletions, 9 of them being novel. 
































































By adding the missing eight ABCC6 exon probes (exons 1, 3, 6, 16, 19, 20, 29, 31) the deletion detection will be 
further improved. Especially the addition of an exon 29 probe would be of interest as many mutations have been 
described in this functionally important protein region (Vanakker et al. 2008). 
 
In conclusion, our approach has increased the ABCC6 mutation detection rate, the mutation spectrum and has 
also confirmed that a second gene locus for PXE is unlikely. In addition our results underline the importance of 
genomic instability in the ABCC6 region. Furthermore, we have demonstrated the heterogeneous nature of the 
ABCC6 whole gene deletions and have shown that most of these expand far beyond the ABCC6 genomic region. 
Our results clearly showed that deletions of various sizes constitute a sizable proportion of ABCC6 mutations 
accounting for some of the previously undetectable alleles. Furthermore, we showed that in certain cases, the 
mutation status of patients may erroneously be interpreted as homozygous due to the technical limitation of 
direct sequencing. As it is now evident that small deletions are more common than previously thought, we 
propose MLPA as an efficient complementary technique to ABCC6 molecular diagnosis. 
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Max.deleted area  
 
Genes deleted  (min.area)  Genes possibly deleted 
3 16,164,551-16,159,020 16,156,390-16,166,980 Not applicable  Not applicable  
13 15,399,818-16,183,616 15,164,187-16,807,118 MPV17L, KIAA04, MIRN48, NDE1, MYH11, 
ABCC1, ABCC6  
NOMO 3, PKD1P1, PKD1P2 
26 14,956,252-16,213,237 14,852,061-16,807,177 PDXDC, NTAN1, RRN3, PKD1P6,  MPV17I, 
KIAA04, MIRN48, NDE1, MYH11, ABCC1, 
ABCC6  
NOMO1, PKD1P3,NPIP, NOMO 3, 
PKD1P1, PKD1P2 
32 16,151,286-16,155,931 16,150,211-16,155,985 Not applicable  Not applicable  
34 15,164,187-17,919,962 15,062,188-18,020,277 MPV17L, KIAA04, MIRN48, NDE1, MYH11, 
ABCC1, ABCC6, NOMO3,PKD1P1, PKD1P2, 
XYLT1 
RRN3 
Minimal en maximal multi-exon deletion sizes as predicted by aCGH.  According to this size range, a prediction was made on the presence or absence of other surrounding 


















































































Table II. Summary of MLPA results and subsequent confirmation strategy for deletions detected by MLPA. 

















/ *, True positive 
 
       
7 p.Arg518Stop 
c.1552C>T 
exon 2 del. 
 










16 IVS21+1G>T Exon 9 del. Identical c.999-?_1176+?del / *, True positive 
20 p.Arg518Stop 
c.1552C>T  
WGD / c.(?_-37)_(*568_?)del 
 
/  








Exon 24 del. / c.3307-904_3506+660del /  
32 c.3144_3145delTT 
 






*, True positive 
Min. (16151286-16155931) 
Max.(16150211-16155985) 








Exon 14 del. 
 





For 11 out of 35 patients a mutation was found using MLPA. Mutations in grey were previously identified, mutations in black were identified by MLPA analysis. 
Confirmation studies revealed the presence of a false positive result for patient 6. For patients 7 and 16, probe and DNA sequence are not 100% identical, but the homozygous 
SNP present does not influence probe binding, as verified for a control sample with the same variant. For multi-exon deletions it is less likely that all consecutive exons have a 
SNP or mutation that influences probe binding, which makes confirmation of these larger deletions unnecessary. pt: patient; WGD: Whole gene deletion. * = SNPs in the 
deleted region are verified and in a homozygous state, which is an argument for a true deletion. ArrayCGH was only performed when fresh DNA could be isolated from 
































































available fibroblasts (“yes”). c.(?_-37)_(*568_?)del denotes a deletion of the entire ABCC6 gene (sequence running from  –37 (cap site) to *568 (polyA-addition site). 
RefSeqNM_001171.5. 
 































































Figure 1. Overview of MLPA results. Each patient with a positive MLPA result, a patient without deletions/duplications 
(negative control) and a positive control (deletion exon 23-29) are shown.  Every bar is the ratio result of 1 probe pair PCR 
product. From left to right: ratio for the ABCC1 probe, ABCC6 exon 30, exon 28-21, exon 18-17, exon 15-7, exon 5, exon 3, 
exon 2, followed by 12 bars representing the 12 control probes (purple bracket). All ratios for the negative control sample are 
approximately 1, indicating that this individual does not show deletions/duplications. As expected, a 0.5 ratio is observed for 
exon 23, 24, 25, 26, 27 and 28 for the positive control sample. Exon 29 is not incorporated in the kit. A ratio of 1.0 for the 
ABCC1 control probe is observed for the positive control sample. 
 


































































Figure 2. Array CGH based results. Red and green lines represent cut-off values and the chromosomal region is indicated 
underneath each panel. (A) Results for patients 3, 13, 26 and 34 with a multi-exon deletion. Patient 3: deletion exon 24-27. 
Region chr.16: 16,156,390- 16,166,980, where ABCC6 exons 24-27 are located, exhibit decreased DNA hybridisation for 






























































patients’ 3 DNA (ratio -1). Patients 13, 26, 34: whole ABCC6 gene deletion. A -1 ratio is observed for region chr16:15,399,818-
16,183,616, chr16: 14,956,252-16,213,237 and chr16: 15,164,187-17,919,962 respectively, suggesting these 3 patients have a 
deletion of several genes surrounding the ABCC6 gene, as further detailed in table 1. (B) Result for patient 32: deletion exon 
30-31. A -1 ratio is observed for region chr.16: 16150211-16155985. 
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